Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparison between depot leuprorelin and daily buserelin in IVF

  • 52 Accesses

  • 13 Citations

Abstract

Objectives

To compare the effects of depot and daily forms of GnRH analogs in IVF programs.

Methods

One hundred seventeen patients undergoing IVF, with no severe male factor, were randomized between two treatment groups. Pituitary desensitization was obtained in group 1 (60 patients) with a single IM injection of leuprorelin (3.75 mg), and in group 2 (57 patients) with buserelin (0.3 mg SC twice daily). In a subgroup of 10 patients (5 for the depot form and 5 for the daily form) several GnRH tests were performed to investigate pituitary desensitization.

Results

No differences were found in the time to reach desensitization. Resumption of pituitary activity occurred in 7 days with the daily form and in about 2 months with the depot form. No significant differences were found in the stimulation pattern, oocyte quality, percentage of fertilization. The pregnancy rate per transfer was slightly, but not significantly, better in the depot group (29.4% vs 25.9%). Implantation rate (11.9% vs 12.3%) and the percentage of miscarriages (26.6% vs 28.5%) were similar.

Conclusion

Depot and daily forms of GnRH analogs are equally effective in superovulation induction for IVF. Considering improved patient compliance and preference, depot forms are advantageous.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Herman A, Ron-El R, Golan A, Nachum H, Soffer Y, Caspi E: Impaired corpus luteum function and other undesidered results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotropin-releasing hormone. Hum Reprod 1992;7:465–468

  2. 2.

    Sopelak VM, Hodgen G: Infusion of gonadotropin-releasing hormone agonist during pregnancy: maternal and fetal responses in primates. Am J Obstet Gynaecol 1987;156:755–760

  3. 3.

    Kang IS, Kuehl TJ, Siler-Khord TM: Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril 1989;52:846–853

  4. 4.

    Porcu E, Dal Prato L, Seracchioli R, Fabbri R, Longhi M, Flamigni C: Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results. Fertil Steril 1994;62:126–132

  5. 5.

    Filicori M, Flamigni C, Cognigini G, Dellai P, Arnone R, Falbo A, Capelli M: Comparison of the suppressive capacity of different depot gonadotropine-releasing hormone and analogs in women. J Clin Endoc Metab 1993;77:130–133

  6. 6.

    Har-Toov J, Brenner SH, Jaffa A, Yavetz H, Peyser MR, Lessing JB: Pregnancy during long-term gonadotropin-releasing hormone agonist therapy associated with clinical pseudomenopause. Fertil Steril 1993;59:446–447

  7. 7.

    Smitz J, Devroey P, Braeckmans P: Management of failed cycles in an IVG/GIFT program with the combination of a GnRH analogue and HMG. Hum Reprod 1987;2:309–314

  8. 8.

    Smitz J, Devroey P, Camus M: The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod 1988;3:585–590

  9. 9.

    Porcu E, Fabbri R, Magrini O, Bonu MA, Sereni E, Ciotti P, Borini A, Seracchioli R, Flamigni C: LHRH analogs and follicular steroidogenesis. Human Reproduction. Proceedings of the 8th Annual Meeting of the ESHRE; 1992 July 5–8; The Hague (The Netherlands). Oxford University Press, 1992:117

  10. 10.

    Tureck RW, Mastroianni L Jr, Blasco L, Strauss JF: Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1982;54:1078–1080

  11. 11.

    Parinaud J, Beaur A, Bourreau E, Vieitez G, Pontonnier G: Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertil Steril 1988;50:597–602

  12. 12.

    Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, Haur F: GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 1989;125:1739–1741

  13. 13.

    Casper RF, Yen SSC: Induction of luteolysis in the human with a long acting analog of luteinizing hormone-releasing factor. Science 1979;205:408–410

  14. 14.

    Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E: Fetal outcome following inadvertant administration of long-acting DTRP6 GnRH microcapsules during pregnancy: a case report. Hum Reprod 1990;5:123–124

  15. 15.

    Caspi E, Ron-El R, Golan A, Nachum H, Herman A, Soffer Y, Weinraub Z: Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone and gonadotropins. Fertil Steril 1989;51:95–99

  16. 16.

    Balasch J, Jové IC, Moreno V, Civico S, Puerto B, Vanrell JA: The comparison of two gonadotropin-releasing hormone agonists in an in vitro fertilization program. Fertil Steril 1992;58:991–994

Download references

Author information

Correspondence to Eleonora Porcu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Porcu, E., Filicori, M., Prato, L.D. et al. Comparison between depot leuprorelin and daily buserelin in IVF. J Assist Reprod Genet 12, 15–19 (1995). https://doi.org/10.1007/BF02214123

Download citation

Key words

  • GnRH analogs
  • IVF
  • superovulation induction
  • depot GnRH analogs
  • daily GnRH analogs